NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee ID2707

Provisional stakeholder list of consultees and commentators

Consultees		Commentators (no right to submit or appeal)	
Company		General	
	EC AG (novocart 3D)	•	All Wales Therapeutics and Toxicology Centre
Patient/carer groups		•	Allied Health Professionals Federation
	on on Pain	•	Board of Community Health Councils in
Arthi	ritis Action		Wales
Arthi	ritis & Musculoskeletal Alliance	•	British National Formulary
• Leor	nard Cheshire Disability	•	Care Quality Commission
	lim Council of Britain	•	Department of Health, Social Services
Natio	onal Rheumatoid Arthritis Society		and Public Safety for Northern Ireland
	Concern	•	Healthcare Improvement Scotland
• Pain	Relief Foundation	•	Medicines and Healthcare Products
• Roya	al Osteoporosis Society		Regulatory Agency
Sout	h Asian Health Foundation	•	National Association of Primary Care
• Spec	cialised Healthcare Alliance	•	National Joint Registry
•	us Arthritis	•	National Pharmacy Association
		•	NHS Alliance
Profession	Professional groups		NHS Confederation
 Asso 	ociation of Anaesthetists	•	Scottish Medicines Consortium
	ociation of Surgeons of Great in and Ireland	•	Welsh Health Specialised Services Committee
• Bone	e Research Society		
Britis	sh Association for Surgery of the	Poss	ible comparator companies
Knee	e	•	OsCell John Charnley Laboratory (NHS
	sh Geriatrics Society		Laboratory) at Robert Jones and Agnes
	sh Institute of Musculoskeletal		Hunt Orthopaedic Hospital, Oswestry
	icine		(autologous stem cell transplantation)
	sh Institute of Radiology	•	Co.don AG (chondrosphere)
	sh Orthopaedic Association	Dala	ant recent are une
	sh Pain Society		vant research groups
	sh Society for Rheumatology	•	Age UK
	sh Society of Rehabilitation	•	Chronic Pain Policy Coalition
	icine	•	Cochrane Musculoskeletal Group
	sh Society of Skeletal Radiology	•	MRC Clinical Trials Unit
	rtered Society of Physiotherapy	•	National Institute for Health Research
	siotherapy Pain Association	٨٠٠	ociated Public Health Groups
	ary Care Rheumatology Society	ASSO	Diciated Public Health Groups
•	al College of Anaesthetists		Public Health England Public Health Wales
 Roya 	al College of General Practitioners	•	

Provisional stakeholder list for the technology appraisal for novocart 3D for treating articular cartilage defects of the knee ID2707 Issue Date: June 2020 . © National Institute for Health and Care Excellence 2020. All rights reserved

Consultees	Commentators (no right to submit or appeal)
 Royal College of Nursing Royal College of Occupational Therapists Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal College of Surgeons Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association 	
Others•Department of Health & Social Care•NHS England•NHS Trafford CCG•NHS Merton CCG•Welsh Government	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

<u>Consultees</u>

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.

Provisional stakeholder list for the technology appraisal for novocart 3D for treating articular cartilage defects of the knee ID2707 Issue Date: June 2020 . © National Institute for Health and Care Excellence 2020. All rights reserved

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary.

All non-company commentators are invited to nominate clinical specialists or patient experts.